Characteristics Associated with Olfactory and Taste Disorders in COVID-19.


Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2021
Historique:
received: 30 01 2021
accepted: 04 05 2021
pubmed: 2 7 2021
medline: 29 9 2021
entrez: 1 7 2021
Statut: ppublish

Résumé

Olfactory and taste disorders (OTDs) have been reported in COVID-19 caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the mechanisms of which remain unclear. We conducted a detailed analysis of OTDs as part of 2 seroepidemiological investigations of COVID-19 outbreaks. Two retrospective cohort studies were conducted in a high school and primary schools of Northern France following a COVID-19 epidemic in February-March 2020. Students, their relatives, and school staff were included. Anti-SARS-CoV-2 antibodies were identified using a flow-cytometry-based assay detecting anti-S IgG. Among 2,004 participants (median [IQR] age: 31 [11-43] years), 303 (15.2%) tested positive for SARS-CoV-2 antibodies. OTDs were present in 91 (30.0%) and 92 (30.3%) of them, respectively, and had 85.1 and 78.0% positive predictive values for SARS-CoV-2 infection, respectively. In seropositive participants, OTDs were independently associated with an age above 18 years, female gender, fatigue, and headache. This study confirms the higher frequency of OTDs in females than males and adults than children. Their high predictive value for the diagnosis of COVID-19 suggests that they should be systematically searched for in patients with respiratory symptoms, fever, or headache. The association of OTDs with headache, not previously reported, suggests that they share a common mechanism, which deserves further investigation.

Identifiants

pubmed: 34198303
pii: 000517066
doi: 10.1159/000517066
pmc: PMC8339025
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

381-386

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Simon Galmiche (S)

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France, simon-galmiche@hotmail.fr.

Timothée Bruel (T)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.

Yoann Madec (Y)

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.

Laura Tondeur (L)

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.

Ludivine Grzelak (L)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
UMR 3569, Centre National de la Recherche Scientifique (CNRS), Paris, France.
Université de Paris, Sorbonne Paris Cité, Paris, France.

Isabelle Staropoli (I)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.

Isabelle Cailleau (I)

Direction de la recherche médicale, Institut Pasteur, Paris, France.

Marie-Noëlle Ungeheuer (MN)

ICAReB platform (Clinical Investigation & Access to Research Bioresources) of the Center for Translational Sciences, Institut Pasteur, Paris, France.

Charlotte Renaudat (C)

ICAReB platform (Clinical Investigation & Access to Research Bioresources) of the Center for Translational Sciences, Institut Pasteur, Paris, France.

Sandrine Fernandes Pellerin (S)

Center for Translational Sciences, Institut Pasteur, Paris, France.

Bruno Hoen (B)

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.
Direction de la recherche médicale, Institut Pasteur, Paris, France.

Olivier Schwartz (O)

Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France.
UMR 3569, Centre National de la Recherche Scientifique (CNRS), Paris, France.
Université de Paris, Sorbonne Paris Cité, Paris, France.
Vaccine Research Institute, Créteil, France.

Arnaud Fontanet (A)

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.
PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH